4-(3-amino-1H-pyrazol-5-yl)benzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3-amino-1H-pyrazol-5-yl)benzonitrile
• 化学式: C₁₀H₈N₄
• 分子量: 184.2
• InChiKey: ZBETZXHARMBOSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.53
• 重原子数：
  14.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.49
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  对氰基苯甲酸甲酯 在 sodium hydride 、 一水合肼 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 、 mineral oil 为溶剂， 反应 6.0h， 生成 4-(3-amino-1H-pyrazol-5-yl)benzonitrile
  参考文献：
  名称：

  [EN] METHODS FOR TREATING NEUROLOGICAL DISORDERS
  [FR] MÉTHODES DE TRAITEMENT DE TROUBLES NEUROLOGIQUES

  摘要：

  This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  公开号：

  WO2023107714A2

文献信息

• [EN] BENZENE SULFONAMIDES AS CCR9 INHIBITORS<br/>[FR] BENZÈNE-SULFONAMIDES À TITRE D'INHIBITEURS DE CCR9
  申请人：NORGINE BV

  公开号：WO2015097122A1

  公开（公告）日：2015-07-02

  The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).

  本发明涉及作为CCR9调节剂有用的化合物，包含这些化合物的组合物，制备它们的方法，以及使用它们的方法。具体而言，本发明涉及能够通过作为部分激动剂、拮抗剂或逆激动剂来调节CCR9受体功能的化合物。这些化合物可能有助于治疗、预防或缓解与CCR9激活相关的疾病或状况，包括炎症和免疫性疾病或状况，如炎症性肠病（IBD）。
• TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS
  申请人：Boivin Roch

  公开号：US20130324547A1

  公开（公告）日：2013-12-05

  Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis

  本公开的实施例涉及四氢吡唑吡嘧啶化合物，其作为Toll样受体7和/或8的拮抗剂或抑制剂，并且它们在治疗全身性红斑狼疮（SLE）和狼疮性肾炎有效的药物组合物中的应用。
• Tetrahydropyrazolopyrimidine compounds
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US10640500B2

  公开（公告）日：2020-05-05

  Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

  本公开的实施方案涉及作为Toll样受体7和/或8的拮抗剂或抑制剂的四氢吡唑嘧啶化合物，以及它们在有效治疗系统性红斑狼疮（SLE）和狼疮肾炎的药物组合物中的用途。
• Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives
  申请人：RICHTER GEDEON NYRT.

  公开号：US10960007B2

  公开（公告）日：2021-03-30

  The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention also relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.

  本发明涉及新的式（I）吡唑并[1,5-a]嘧啶衍生物或其药学上可接受的盐、生物活性代谢物、原药、外消旋体、对映体、非对映异构体、溶液和水合物，可作为 GABAB 受体正异位调节剂。本发明还涉及生产此类化合物的工艺。本发明进一步涉及包含此类化合物的药物组合物（可选择与两种或两种以上不同的治疗剂组合），以及此类化合物在治疗由 GABAB 受体正性异位调节机制介导和调节的疾病和病症的方法中的用途。本发明还提供了一种用于治疗此类疾病的药物的制造方法。
• Discovery of mixed type thymidine phosphorylase inhibitors endowed with antiangiogenic properties: Synthesis, pharmacological evaluation and molecular docking study of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones. Part II
  作者：Hriday Bera、Probir kumar Ojha、Bee Jen Tan、Lingyi Sun、Anton V. Dolzhenko、Wai-Keung Chui、Gigi Ngar Chee Chiu

  DOI：10.1016/j.ejmech.2014.03.063

  日期：2014.5

  In our drug discovery program, a series of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones were designed, synthesized and evaluated for their TP inhibitory potential. All the synthesized analogues conferred a varying degree of TP inhibitory activity, comparable or better than positive control, 7-deazaxanthine (7-DX, 2) (IC50 value = 42.63 mu M). A systematic approach to the lead optimization identified compounds 3c and 4a as the most promising TP inhibitors, exhibiting mixed mode of enzyme inhibition. Moreover, selected compounds demonstrated the ability to attenuate the expression of the angiogenic markers (viz. MMP-9 and VEGF) in MDA-MB-231 cells at sublethal concentrations. In addition, molecular docking studies revealed the plausible binding orientation of these inhibitors towards TP, which was in accordance with the experimental results. Taken as a whole, these compounds would constitute a new direction for the design of novel TP inhibitors with promising antiangiogenic properties. (C) 2014 Elsevier Masson SAS. All rights reserved.